Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Kiniksa Pharmaceuticals Ltd (KNSA)

Kiniksa Pharmaceuticals Ltd (KNSA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,207,024
  • Shares Outstanding, K 68,232
  • Annual Sales, $ 0 K
  • Annual Income, $ -161,380 K
  • 60-Month Beta -0.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.87
Trade KNSA with:

Options Overview

Details
  • Implied Volatility 96.00%
  • Historical Volatility 63.15%
  • IV Percentile 81%
  • IV Rank 19.68%
  • IV High 191.31% on 03/16/21
  • IV Low 72.65% on 12/21/20
  • Put/Call Vol Ratio 0.02
  • Today's Volume 636
  • Volume Avg (30-Day) 811
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 11,830
  • Open Int (30-Day) 6,489

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.74
  • Number of Estimates 3
  • High Estimate -0.39
  • Low Estimate -0.92
  • Prior Year -0.48
  • Growth Rate Est. (year over year) -54.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.50 +4.77%
on 04/13/21
23.90 -32.05%
on 03/15/21
-6.98 (-30.06%)
since 03/12/21
3-Month
15.50 +4.77%
on 04/13/21
24.70 -34.25%
on 02/22/21
-3.33 (-17.02%)
since 01/14/21
52-Week
14.51 +11.92%
on 09/04/20
28.67 -43.36%
on 06/29/20
-0.91 (-5.31%)
since 04/14/20

Most Recent Stories

More News
Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients

- Primary endpoint achieved: the proportion of patients alive and free of mechanical ventilation at Day 29 was 12.3 percentage points higher with mavrilimumab versus placebo (p=0.1224 met predefined statistical...

KNSA : 16.24 (+3.44%)
Kiniksa Announces Commercial Availability of ARCALYST (R) (rilonacept) for Recurrent Pericarditis

- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis -

KNSA : 16.24 (+3.44%)
Thinking about buying stock in SenesTech, Marker Therapeutics, Strongbridge Biopharma, Kiniksa Pharmaceuticals, or Rockwell Medical?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNES, MRKR, SBBP, KNSA, and RMTI.

KNSA : 16.24 (+3.44%)
MRKR : 2.12 (+1.44%)
RMTI : 1.0000 (+3.08%)
SBBP : 2.49 (unch)
SNES : 1.5700 (-0.63%)
Kiniksa Announces FDA Approval of ARCALYST (R) (rilonacept) for Recurrent Pericarditis

- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis -

KNSA : 16.24 (+3.44%)
Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today announced...

KNSA : 16.24 (+3.44%)
Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity

- Strong execution across pipeline of immune-modulating assets throughout 2020 enables multiple milestones in 2021 -

KNSA : 16.24 (+3.44%)
New Strong Sell Stocks for January 27th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

ISRG : 785.83 (-1.09%)
DBVT : 6.45 (+9.51%)
TVTY : 23.37 (+1.26%)
KNSA : 16.24 (+3.44%)
SFT : 8.00 (-2.50%)
Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones

- PDUFA goal date of March 21, 2021 for rilonacept in recurrent pericarditis -

KNSA : 16.24 (+3.44%)
Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 39 Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 4:30 p.m. Eastern Time.

JPM : 151.21 (-1.87%)
KNSA : 16.24 (+3.44%)
Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation

- Early signal of efficacy with trends toward lower mortality and shorter duration of mechanical ventilation in patients treated with mavrilimumab -

KNSA : 16.24 (+3.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts,...

See More

Key Turning Points

3rd Resistance Point 18.26
2nd Resistance Point 17.57
1st Resistance Point 16.90
Last Price 16.24
1st Support Level 15.55
2nd Support Level 14.86
3rd Support Level 14.19

See More

52-Week High 28.67
Fibonacci 61.8% 23.26
Fibonacci 50% 21.59
Fibonacci 38.2% 19.92
Last Price 16.24
52-Week Low 14.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar